ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,672Medicare Part D Prescriptions Filled, Including Refills

Rank: 71 out of 198

$446K Total Retail Price of All Prescriptions

Rank: 75 out of 198

392 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
23% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 392 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

9% of this provider’s 392 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

2% of this provider’s 7,393 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
LEVOTHYROXINE SODIUM 395 371 1 1
SIMVASTATIN 369 336 2 2
OMEPRAZOLE 289 236 3 3
LISINOPRIL 273 241 4 6
AMLODIPINE BESYLATE 266 255 5 4
METOPROLOL SUCCINATE 247 234 6 11
FUROSEMIDE 237 234 7 5
ATORVASTATIN CALCIUM 162 147 8 12
WARFARIN SODIUM 155 140 9 7
METOPROLOL TARTRATE 151 139 10 10
PRAVASTATIN SODIUM 132 121 11 19
ALENDRONATE SODIUM 122 112 12 21
ATENOLOL 118 110 13 17
DONEPEZIL HCL 114 114 14 28
PANTOPRAZOLE SODIUM 111 107 15 31
HYDROCODONE-ACETAMINOPHEN 109 64 S3 16 8
POTASSIUM CHLORIDE 108 95 17 9
ZOLPIDEM TARTRATE 106 70 18 22
CITALOPRAM HBR 102 75 19 20
GABAPENTIN 98 75 20 14
MELOXICAM 93 60 21 30
LOSARTAN POTASSIUM 92 90 22 18
TRIAMTERENE-HCTZ 91 77 23 32
ALLOPURINOL 88 84 24 23
SYNTHROID 83 65 25 36
CLOPIDOGREL 82 80 26 42
TRAMADOL HCL 80 68 27 15
METFORMIN HCL 78 48 28 13
DIOVAN 78 68 28 34
NEXIUM 76 56 30 40
LISINOPRIL-HYDROCHLOROTHIAZIDE 70 70 31 38
PREDNISONE 70 64 31 29
FLUTICASONE PROPIONATE 69 38 33 39
ISOSORBIDE MONONITRATE ER 66 66 34 60
TRAZODONE HCL 64 46 35 50
CELEBREX 62 56 36 59
BENAZEPRIL HCL 61 59 37 45
AMITRIPTYLINE HCL 57 49 R 38 69
SULFAMETHOXAZOLE-TRIMETHOPRIM 57 44 38 90
CYMBALTA 57 38 38 48
DOXAZOSIN MESYLATE 57 56 38 96
PLAVIX 51 50 42 66
SERTRALINE HCL 51 32 42 25
ESTRADIOL 51 51 R 42 172
ESCITALOPRAM OXALATE 51 41 42 53
IPRATROPIUM-ALBUTEROL 51 51 42 180
PEN NEEDLE 50 49 47 114
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 19, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.